Similarly, a novel USP7 inhibitor, XL177A, was cytotoxic against MM in preclinical models and appeared to target supporting plasmacytoid dendritic cells to restore anti-MM immunity[58,66]. The gene discussed is USP7; the disease is Miyoshi myopathy.